Sprint Bioscience
1.306 SEK +1.24%1 investor is following this company
Sprint Bioscience is a research company. The company develops pharmaceutical candidates that alone or in combination with other pharmaceuticals can fight cancer. The company has a project portfolio focused on attacking parts of cancer cell processes. The company's business model is based on developing projects parallel in the preclinical phase to subsequently enter into licensing agreements with the global pharmaceutical industry. The company was founded in 2009 and is headquartered in Huddinge.
Revenue
50.49M
EBIT %
-1.68 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
SPRINT
Daily low / high price
1.22 / 1.306
SEK
Market cap
91.19M SEK
Turnover
201.83K SEK
Volume
158K
Financial calendar
General meeting
2024-05-08
Interim report
2024-05-08
Interim report
2024-08-28
Interim report
2024-10-30
Annual report
2025-02-12
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
First Venture Sweden | 14.1 % | 14.1 % |
Jan Ivar Nordqvist | 9.2 % | 9.2 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Positiva prekliniska resultat i Sprint Bioscience onkologiprogram riktat mot TREX1
Årsredovisning 2023
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools